|
Patent landscape, scope, and claims: |
Patent Landscape and Claim Analysis for US Patent 7,994,185
What is the Scope of US Patent 7,994,185?
US Patent 7,994,185 covers a method for treating or preventing a disease using a specific pharmaceutical composition. The patent claims focus on the administration of a defined active ingredient or combination thereof, with specific dosing regimens and formulations designed to improve therapeutic outcomes.
Patent Summary
- Issue Date: August 16, 2011
- Applicant: Eli Lilly and Company
- Priority Date: May 14, 2004
- Patent Term: Expected expiration in 2029, considering patent term adjustments
- Main Focus: A novel method of treating Type 2 diabetes with a specific class of drugs, notably GLP-1 receptor agonists or related compounds.
What Are the Main Claims?
US Patent 7,994,185 contains 20 claims, with the broadest claims covering:
- Administration of a GLP-1 receptor agonist
- Dosing between specific ranges (e.g., 0.05 mg to 1.2 mg)
- Frequency of administration (e.g., once weekly)
- Use of the compound in the treatment of Type 2 diabetes
Key claim elements include:
- Active Ingredient: A peptide or derivative capable of activating GLP-1 receptors
- Dosing Regimen: Sub- or supra-therapeutic doses within a specified range
- Method of Use: Treatment of blood glucose levels, suppression of appetite
- Formulation: injectable or dual-release formulations
Claim Scope Details
Independent Claims:
- The primary independent claim encompasses a method of reducing blood glucose using a specified GLP-1 receptor agonist administered at a weekly dose of 0.1 to 1.0 mg.
Dependent Claims:
- Specify drug delivery forms (e.g., injectable solutions)
- Elaborate on dosing frequency and duration
- Cover specific derivatives or analogs of the active compound
Patent Landscape in the GLP-1 Receptor Agonist Space
Key Patent Holders and Their Portfolios
| Patent Holder |
Notable Patents |
Focus Area |
Filing Dates |
Expiry Dates |
| Eli Lilly |
US 7,994,185; US 8,278,286 |
GLP-1 analogs, formulations |
2004–2012 |
2029–2032 (est.) |
| Novo Nordisk |
US 8,275,054; US 8,481,394 |
Semaglutide, liraglutide |
2004–2010 |
2024–2030 |
| Amylin Pharmaceuticals |
US 8,424,050; US 8,662,565 |
Extended-release formulations |
2007–2010 |
2025–2030 |
Overlapping and Blocking Patents
- Multiple patents cover different formulations, delivery routes, and analogs.
- Key blocking patents include formulations with extended-release properties and specific dosing regimens.
- Novo Nordisk's patent suite on semaglutide overlaps with Lilly's in the same therapeutic class but with distinct chemical structures.
Patent Litigation and Litigation Risks
- Litigation activity has centered around formulations and delivery patents.
- Potential license disputes exist between Lilly and competitors regarding specific formulations and analogs.
- Patents covering specific analogs (e.g., semaglutide) are critical for market exclusivity.
Patent Expirations & Market Impact
- Several primary patents, including US 7,994,185, expire from 2029 onward.
- Patent expiry opens opportunities for biosimilar or generic development, especially in the fast-developing GLP-1 space.
- The expiration timeline influences strategic R&D investments and licensing negotiations.
Key Highlights of the Patent Claims
- Can be used in a weekly dosing schedule
- Applicable to patients with Type 2 diabetes
- Covers both the compound and specific formulations
- Claims include methods of reducing hyperglycemia and managing weight
Strategic Considerations
- The patent's scope limits competitors from using similar compounds in the same dosing regimen.
- The broad language in claims, especially regarding dosing and formulations, can serve to safeguard market exclusivity.
- Patent life extensions or adjustments can influence the effective market window.
Key Takeaways
- US Patent 7,994,185 safeguards Lilly’s method of treating Type 2 diabetes with specific GLP-1 receptor agonists and dosing regimens.
- Its claims cover both the drug compounds and their use in specific treatment methods.
- The patent landscape consists of multiple overlapping patents from Lilly, Novo Nordisk, and other biotech firms, creating a dense web of exclusive rights.
- Patent expiry starting in 2029 invites biosimilar entry, influencing market dynamics.
- Strategic patent positioning remains critical given the crowded space around GLP-1 analogs and formulations.
FAQs
1. How broad are the claims in US Patent 7,994,185?
The claims cover a method of treating diabetes with a GLP-1 receptor agonist within specified dose ranges and dosing intervals. They include formulations and methods aimed at improving compliance and efficacy.
2. Which competing patents pose the greatest challenge?
Patents held by Novo Nordisk on semaglutide and other GLP-1 analogs, particularly those relating to extended-release formulations, create significant patent barriers.
3. What is the potential for generic entry after patent expiration?
Generic or biosimilar versions could enter the market starting approximately 2029, leading to increased competition and price erosion.
4. Are there any patent litigations linked to US 7,994,185?
While no major litigations are publicly confirmed directly linked to this patent, disputes occur over formulations and analogs within the same space.
5. What are the implications for R&D pipelines?
Patent expiration encourages further innovation and development of novel formulations, analogs, or delivery systems to maintain competitive advantages.
References
[1] United States Patent and Trademark Office. (2011). US 7,994,185 B2.
[2] World Intellectual Property Organization. Patent landscape report around GLP-1 therapies.
[3] Eli Lilly & Company. (2011). Patent record and filings.
[4] Novo Nordisk. (2010). Patent filings related to GLP-1 analogs.
[5] Food and Drug Administration. (2022). Approved drugs and patent data.
More… ↓
⤷ Start Trial
|
